Send us a text

• Petition · Urgent Call for U.S. Children to Have Access to an FDA-Approved Low-Dose Atropine - United States · Change.org

About Patrick Johnson, Ph.D.

Patrick Johnson joined Sydnexis as Chief Business Officer in 2017. He was instrumental in the Series A and B financings at Sydnexis as well as the corporate alliance with Santen Pharmaceuticals that was established in 2021.

Prior to his role at Sydnexis, Patrick was the Vice President of Corporate and Business Development at Allergan, a publicly traded, large-cap pharmaceutical company. At Allergan, Patrick was responsible for establishing dozens of corporate partnerships as well as mergers and acquisitions in eyecare (Allergan’s largest therapeutic area) and drug delivery. Prior to Allergan, Patrick was a co-founder of Chimeros, a biotechnology start-up company founded in Santa Barbara in 2005, where he was Vice President of Business Development in addition to leading scientific teams as Director of Biology. Before co-founding Chimeros, Patrick was an adjunct faculty member at the University of California, Santa Barbara (USCB) where he was simultaneously conducting research in the Center for the Study of Macular Degeneration while teaching classes in Neurobiology, Developmental Biology, Introductory Biology, and Biotechnology and Society.

Patrick holds a B.S. in biopsychology and a Ph.D. in molecular, cellular, and developmental biology, both from USCB. His doctoral research focused on the development of visual pathways in mammals and his post-doctoral research focused on diseases of the eye, spanning both acute injury (retinal detachment) and chronic disease (age-related macular degeneration).